94.90
price up icon0.32%   0.30
after-market After Hours: 94.90
loading
Merus N V stock is traded at $94.90, with a volume of 2.03M. It is up +0.32% in the last 24 hours and up +37.76% over the past month. Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$94.60
Open:
$94.62
24h Volume:
2.03M
Relative Volume:
0.98
Market Cap:
$7.18B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-24.03
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
+0.32%
1M Performance:
+37.76%
6M Performance:
+109.58%
1Y Performance:
+79.67%
1-Day Range:
Value
$94.58
$94.96
1-Week Range:
Value
$94.38
$95.06
52-Week Range:
Value
$33.19
$95.06

Merus N V Stock (MRUS) Company Profile

Name
Name
Merus N V
Name
Phone
31 030 253 8800
Name
Address
YALELAAN 62, 3584 CM UTRECHT
Name
Employee
260
Name
Twitter
@MerusNV
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
MRUS's Discussions on Twitter

Compare MRUS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MRUS
Merus N V
94.90 7.17B 35.93M -244.56M -157.31M -3.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.39 107.73B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
654.48 62.04B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
475.91 62.73B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
836.39 51.09B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
165.29 34.67B 398.11M -1.03B -868.57M -5.7032

Merus N V Stock (MRUS) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-17-25 Initiated Barclays Overweight
Aug-25-25 Initiated Alliance Global Partners Buy
Feb-13-25 Initiated Piper Sandler Overweight
Feb-07-25 Initiated Wells Fargo Overweight
Nov-21-24 Initiated Goldman Buy
Oct-24-24 Initiated UBS Buy
Mar-28-24 Initiated Truist Buy
Mar-04-24 Reiterated Needham Buy
Nov-02-23 Initiated Canaccord Genuity Buy
Aug-21-23 Initiated TD Cowen Outperform
Aug-02-22 Initiated Stifel Buy
Feb-11-22 Initiated BMO Capital Markets Outperform
Feb-10-22 Initiated Needham Buy
Nov-17-21 Resumed Guggenheim Buy
Jun-07-21 Upgrade Citigroup Neutral → Buy
Apr-08-21 Initiated William Blair Outperform
Mar-16-21 Initiated SVB Leerink Outperform
Jun-26-20 Initiated H.C. Wainwright Buy
May-27-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-20-19 Resumed Guggenheim Buy
Jun-28-19 Initiated ROTH Capital Buy
Apr-12-19 Resumed Guggenheim Buy
Apr-03-19 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-27-19 Initiated Berenberg Buy
Jan-02-18 Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-15-17 Initiated RBC Capital Mkts Outperform
Mar-21-17 Downgrade Citigroup Buy → Neutral
Dec-22-16 Upgrade Citigroup Neutral → Buy
Nov-07-16 Downgrade Citigroup Buy → Neutral
Jun-13-16 Initiated Citigroup Buy
Jun-13-16 Initiated Guggenheim Buy
Jun-13-16 Initiated Wedbush Outperform
View All

Merus N V Stock (MRUS) Latest News

pulisher
07:04 AM

What market sentiment indicators show for Merus N.V. (2GH) stockNew Guidance & Low Risk Entry Point Tips - newser.com

07:04 AM
pulisher
04:15 AM

Will Merus N.V. stock sustain high P E ratios2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - newser.com

04:15 AM
pulisher
03:56 AM

What risks investors should watch in Merus N.V. stockWeekly Stock Recap & Daily Profit Maximizing Tips - newser.com

03:56 AM
pulisher
03:16 AM

Can Merus N.V. stock double in next 5 yearsJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com

03:16 AM
pulisher
02:41 AM

Is Merus N.V. stock a buy before product launches2025 Fundamental Recap & AI Powered Trade Plan Recommendations - newser.com

02:41 AM
pulisher
02:18 AM

Why Merus N.V. stock remains on buy listsJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com

02:18 AM
pulisher
02:15 AM

Is Merus N.V. stock resilient to inflationJuly 2025 Macro Moves & Safe Capital Growth Stock Tips - newser.com

02:15 AM
pulisher
01:28 AM

Market reaction to Merus N.V.’s recent newsWeekly Market Outlook & Stock Portfolio Risk Control - newser.com

01:28 AM
pulisher
01:17 AM

Why Merus N.V. (2GH) stock could outperform next year2025 Market Outlook & Daily Technical Stock Forecast Reports - newser.com

01:17 AM
pulisher
12:40 PM

Can Merus N.V. (2GH) stock sustain revenue momentumDay Trade & AI Enhanced Execution Alerts - newser.com

12:40 PM
pulisher
Oct 27, 2025

Key metrics from Merus N.V.’s quarterly dataMarket Performance Report & High Accuracy Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Why Merus N.V. stock appeals to dividend seekers2025 Price Targets & Capital Protection Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is Merus N.V. stock a dividend growth opportunity2025 Fundamental Recap & Stock Portfolio Risk Management - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

Merus N.V.’s Zenocutuzumab Study Termination: Market Implications - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Will Merus N.V. stock deliver better than expected guidanceWeekly Stock Report & Technical Confirmation Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is Merus N.V. stock attractive for income investorsEarnings Performance Report & Fast Entry Momentum Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

How big funds are accumulating Merus N.V. (2GH) stock2025 Valuation Update & Long-Term Growth Stock Strategies - newser.com

Oct 27, 2025

Merus N V Stock (MRUS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Merus N V Stock (MRUS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Silverman Peter B.
COO & GC
Jul 17 '25
Sale
60.00
25,000
1,500,000
0
$36.41
price down icon 2.47%
$91.65
price down icon 1.56%
$29.13
price up icon 0.34%
$105.09
price down icon 0.85%
biotechnology ONC
$316.85
price up icon 0.47%
$165.29
price up icon 0.80%
Cap:     |  Volume (24h):